364,000 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Bought by Acuta Capital Partners LLC

Acuta Capital Partners LLC acquired a new stake in Acelyrin, Inc. (NASDAQ:SLRN) in the third quarter, HoldingsChannel.com reports. The firm acquired 364,000 shares of the company’s stock, valued at approximately $1,795,000. Acelyrin makes up about 1.5% of Acuta Capital Partners LLC’s investment portfolio, making the stock its 21st largest position.

A number of other large investors have also recently bought and sold shares of the business. Acadian Asset Management LLC purchased a new stake in Acelyrin in the 2nd quarter valued at approximately $590,000. Jacobs Levy Equity Management Inc. acquired a new position in shares of Acelyrin during the 1st quarter valued at about $3,961,000. Almitas Capital LLC purchased a new position in Acelyrin during the second quarter worth approximately $1,659,000. Los Angeles Capital Management LLC acquired a new position in Acelyrin in the second quarter valued at $693,000. Finally, Vanguard Group Inc. lifted its stake in shares of Acelyrin by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 6,237,543 shares of the company’s stock valued at $42,103,000 after purchasing an additional 81,633 shares in the last quarter. Institutional investors and hedge funds own 87.31% of the company’s stock.

Acelyrin Trading Down 1.5 %

NASDAQ SLRN opened at $4.57 on Thursday. The company has a market cap of $458.51 million, a P/E ratio of -1.86 and a beta of 1.98. Acelyrin, Inc. has a 1 year low of $3.36 and a 1 year high of $8.89. The company has a fifty day simple moving average of $5.39 and a 200 day simple moving average of $5.03.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on SLRN shares. Morgan Stanley lowered their target price on Acelyrin from $13.00 to $6.00 and set an “equal weight” rating for the company in a research note on Monday, August 19th. Wells Fargo & Company boosted their price objective on Acelyrin from $13.00 to $15.00 and gave the company an “overweight” rating in a research report on Wednesday, October 16th. HC Wainwright lifted their price target on Acelyrin from $6.00 to $8.00 and gave the company a “neutral” rating in a report on Thursday, November 14th. Finally, Piper Sandler lowered their target price on shares of Acelyrin from $68.00 to $20.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 14th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Acelyrin has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.